Consolidated Statements of Operations (Unaudited) - USD ($)		3 Months Ended
		Mar. 31, 2025	Mar. 31, 2024
Income Statement [Abstract]
Net Revenue		$ 23,434,096	$ 18,536,638
Cost of goods sold		1,834,967	1,890,046
Gross profit		21,599,129	16,646,592
Operating expenses
Selling, general and administrative		21,440,610	16,192,259
Research and development		1,114,138	946,298
Depreciation and amortization		1,124,410	1,105,420
Change in fair value of earnout liabilities			(65,678)
Total operating expenses		23,679,158	18,178,299
Operating loss		(2,080,029)	(1,531,707)
Other income (expense)
Interest expense		(1,317,092)	(267,336)
Share of losses from equity method investments		(143,608)
Interest income		3,672
Gain on disposal of property and equipment		9,674
Total other income (expense)	[1]	(1,447,354)	(267,336)
Net loss		(3,527,383)	(1,799,043)
Less: Net loss attributable to noncontrolling interest		(206)	(34,859)
Net loss attributable to Sanara MedTech shareholders		$ (3,527,177)	$ (1,764,184)
Net loss per share of common stock, basic		$ (0.41)	$ (0.21)
Net loss per share of common stock, diluted		$ (0.41)	$ (0.21)
Weighted average number of common shares outstanding, basic		8,570,104	8,419,528
Weighted average number of common shares outstanding, diluted		8,570,104	8,419,528

[1] For the three months ended March 31, 2025, other expense included interest expense, share of losses from equity method investments offset by interest income and gain on disposal of property and equipment. For the three months ended March 31, 2024, other expense included interest expense.